# Parabilis Medicines, Inc. (PBLS) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1657677 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/PBLS) · [JSON](https://www.pops4.com/boards/company/PBLS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-09-02 ([filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526380171/0001193125-26-380171-index.htm))

## Recent filings

- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526391952/0001193125-26-391952-index.htm)
- 8-K · filed 2026-09-02 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526380171/0001193125-26-380171-index.htm)
- 8-K · filed 2026-08-25 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526365132/0001193125-26-365132-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526349168/0001193125-26-349168-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/0001193125-26-347869-index.htm)
- 8-K · filed 2026-06-11 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001657677.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1657677

## Cite

POPS4, Edgar & Edgarette: Parabilis Medicines, Inc. (PBLS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/PBLS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.